Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myelomaarticle Published on 2023-06-212024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] Ixazomib Multiple myeloma proteasome inhibitor relapsed/refractory disease [DOI] 10.1007/s00277-023-05212-7 PMC 바로가기 [Article Type] article
Chronic Administration of Non-Constitutive Proteasome Inhibitor Modulates Long-Term Potentiation and Glutamate Signaling-Related Gene Expression in Murine Hippocampus비구성 프로테아좀 억제제의 만성 투여가 생쥐 해마에서 장기 강화 및 글루타메이트 신호 전달 관련 유전자 발현을 조절한다.Article Published on 2023-05-032024-08-19 Journal: International Journal of Molecular Sciences [Category] 파상풍, [키워드] non-constitutive proteasomes ONX-0914 proteasome proteasome inhibitor synaptic plasticity.
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing SurveillanceOriginal Article Published on 2021-10-122024-09-04 Journal: Internal medicine (Tokyo, Japan) [Category] 대상포진, [키워드] Adverse drug reaction Ixazomib Multiple myeloma post-marketing all-case surveillance proteasome inhibitor Safety [DOI] 10.2169/internalmedicine.7768-21 PMC 바로가기 [Article Type] Original Article
Nocardia farcinica Brain Abscess in a Multiple Myeloma Patient Treated with Proteasome Inhibitor: A Case Report and Review of the LiteratureCase Report Published on 2021-09-132024-09-02 Journal: Brain Sciences [Category] 대상포진, [키워드] Brain abscess Multiple myeloma Nocardia farcinica proteasome inhibitor [DOI] 10.3390/brainsci11091204 PMC 바로가기 [Article Type] Case Report
NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 PatientsImmunology Published on 2020-12-102022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, 신종인플루엔자, [키워드] acute respiratory distress amplifying approach cascade cell interaction cellular chemokine chemokines clinical manifestation cough COVID-19 COVID-19 patients Critical cytokine Cytokine storm Cytokines death dysregulated Effect elevated expected febrile illness Hypothesis infected with SARS-CoV-2 Inflammatory response Mild Mild symptom much higher multiple organ failure NF-kappaB NF-κB NSAID pathway Patient Perspective Potential Prevent pro-inflammatory pro-inflammatory cytokine proteasome inhibitor provide SARS-CoV-2 (2019-nCoV) severity Severity of disease Stage syndrome synergistic target Therapeutic approach therapeutic potential triggering [DOI] 10.3389/fimmu.2020.598444 PMC 바로가기 [Article Type] Immunology
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case seriesResearch Article Published on 2019-05-142024-09-02 Journal: BMC Ophthalmology [Category] 대상포진, [키워드] blepharitis bortezomib Chalazia Chemotherapy eyelid Multiple myeloma Plasma cell disorder proteasome inhibitor [DOI] 10.1186/s12886-019-1118-x PMC 바로가기 [Article Type] Research Article
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 studyResearch Published on 2017-10-032024-09-02 Journal: Experimental Hematology & Oncology [Category] 대상포진, [키워드] Advanced malignancy Carfilzomib hepatic impairment oncology pharmacokinetics proteasome inhibitor [DOI] 10.1186/s40164-017-0086-1 PMC 바로가기 [Article Type] Research
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation studyResearch Published on 2017-07-062024-09-02 Journal: Journal of Hematology & Oncology [Category] 대상포진, [키워드] China Ixazomib Multiple myeloma oral overall survival progression-free survival proteasome inhibitor Relapsed/refractory [DOI] 10.1186/s13045-017-0501-4 PMC 바로가기 [Article Type] Research
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaHaematological Malignancy Published on 2017-05-092024-09-04 Journal: British Journal of Haematology [Category] 대상포진, [키워드] Dosing Ixazomib Multiple myeloma proteasome inhibitor Toxicity [DOI] 10.1111/bjh.14733 PMC 바로가기 [Article Type] Haematological Malignancy
Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malariaarticle Published on 2015-11-302024-09-01 Journal: Parasite Immunology [Category] 말라리아, [키워드] Brain cerebral malaria cross-presentation malaria proteasome inhibitor [Article Type] article